Pradat P, Tillmann H L, Sauleda S, Braconier J-H, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban J-I, Hadziyannis S, Rizzetto M, Thomas H, Manns M P, Trepo C
Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
J Viral Hepat. 2007 Aug;14(8):556-63. doi: 10.1111/j.1365-2893.2006.00829.x.
The aims of the study were to verify the long-term effect of time on viral clearance in hepatitis C virus (HCV) patients and to find out factors possibly associated with disease progression. A total of 1641 patients recruited from eight European centres in 1996-1997 were re-analysed 5-7 years after inclusion. The occurrence of decompensated cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation was analysed in relation to different host and viral factors. Ninety-three per cent of the HCV patients who had cleared the virus (spontaneously or after antiviral therapy) remained HCV-RNA-negative during follow up and may be considered as 'cured'. Among patients who were sustained responders at inclusion, 2.3% developed liver complications during follow up, and 31% of non-responders did. Advanced age at infection and presence of the human leucocyte antigen (HLA) DRB11201-3 allele were possibly associated with a higher rate of progression to decompensated cirrhosis or HCC. Decompensated cirrhosis might be further associated with male gender, non-response to previous therapy, and lack of HLA DRB11301 allele, whereas HCC seems to be associated with the presence of the HLA DQ02 allele. Long-term follow up of HCV patients indicates that virological response persists over time and is associated with a very low incidence of liver complications. Advanced age at inclusion, advanced age at infection, viral genotype 1, non-response to previous therapy and possibly some specific HLA alleles are factors independently associated with a faster rate of progression towards liver complications. The large proportion of patients lost to follow up stresses the need for a strengthened and optimized management of HCV patients.
该研究的目的是验证时间对丙型肝炎病毒(HCV)患者病毒清除的长期影响,并找出可能与疾病进展相关的因素。对1996年至1997年从欧洲八个中心招募的1641例患者在纳入研究5至7年后进行了重新分析。分析了失代偿期肝硬化、肝细胞癌(HCC)和肝移植的发生情况与不同宿主和病毒因素的关系。93%的HCV患者(自发或抗病毒治疗后)病毒清除者在随访期间HCV-RNA仍为阴性,可视为“治愈”。在纳入时持续应答的患者中,2.3%在随访期间出现肝脏并发症,而无应答者中这一比例为31%。感染时年龄较大和存在人类白细胞抗原(HLA)DRB11201-3等位基因可能与进展为失代偿期肝硬化或HCC的较高发生率相关。失代偿期肝硬化可能进一步与男性性别、对先前治疗无应答以及缺乏HLA DRB11301等位基因有关,而HCC似乎与HLA DQ02等位基因的存在有关。HCV患者的长期随访表明,病毒学应答随时间持续存在,且与肝脏并发症的低发生率相关。纳入时年龄较大、感染时年龄较大、病毒基因型1、对先前治疗无应答以及可能的一些特定HLA等位基因是与向肝脏并发症进展更快速度独立相关的因素。大量患者失访强调了加强和优化HCV患者管理的必要性。